XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 84.20%375.62M | -20.16%58.11M | -41.34%62.24M | -33.74%104.4M | 213.85%150.87M | 12.15%203.92M | -49.89%72.78M | 446.39%106.09M | 286.86%157.57M | -462.59%-132.52M |
Net income from continuing operations | -208.24%-217.99M | -625.83%-289.52M | -31.60%46.44M | -152.00%-32.29M | -48.44%57.38M | 1,726.26%201.4M | 85.72%-39.89M | -24.55%67.9M | -30.94%62.1M | 0.69%111.29M |
Operating gains losses | 69.18%4.6M | 295.69%9.91M | -252.07%-7.7M | -110.22%-111K | 54.00%2.5M | -41.06%2.72M | -151.71%-5.06M | 1,031.25%5.07M | 176.59%1.09M | 150.50%1.63M |
Depreciation and amortization | -2.58%987.41M | -12.03%270.29M | 11.49%250.09M | -11.30%238.66M | 7.25%228.38M | -9.15%1.01B | -27.88%307.25M | -7.67%224.31M | 16.34%269.06M | -1.16%212.95M |
Deferred tax | -226.80%-63.06M | -213.78%-53.21M | -212.28%-4.15M | -130.56%-1.69M | 36.02%-4.01M | 198.12%49.74M | 148.22%46.76M | -69.63%3.7M | -56.29%5.54M | -129.25%-6.27M |
Other non cash items | 92.44%74.72M | 512.39%49.9M | -44.62%9.37M | 66.17%11.01M | -37.82%4.44M | -89.54%38.83M | -97.66%8.15M | 145.26%16.91M | -13.59%6.63M | -11.93%7.14M |
Change In working capital | 31.37%-835.62M | 24.57%-237.7M | -8.90%-237.58M | 1.34%-216.45M | 69.05%-143.9M | 9.32%-1.22B | -1.80%-315.13M | 35.83%-218.17M | 28.87%-219.38M | -20.82%-464.9M |
-Change in receivables | -10.04%30.89M | 190.42%12.87M | 126.95%1.52M | -137.09%-14.22M | 93.19%30.7M | -51.21%34.33M | 51.47%-14.24M | -113.68%-5.65M | 83.39%38.33M | -57.63%15.89M |
-Change in prepaid assets | 108.24%215.03M | 180.76%30.96M | 182.10%40.21M | 56.40%80.25M | -16.34%63.61M | 403.08%103.26M | -141.20%-38.34M | -56.38%14.25M | 204.84%51.31M | 4,080.73%76.03M |
-Change in payables and accrued expense | 37.75%-122.48M | 20.36%-11.17M | -63.84%-34.13M | 8.82%-36.54M | 66.65%-40.63M | -375.18%-196.76M | -108.51%-14.03M | 22.42%-20.83M | -485.13%-40.08M | -58.46%-121.82M |
-Change in other working capital | 17.21%-959.06M | -8.79%-270.36M | -19.06%-245.18M | 8.55%-245.94M | 54.58%-197.58M | 20.14%-1.16B | 42.09%-248.53M | 46.80%-205.94M | 7.51%-268.94M | -26.63%-435.01M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 84.20%375.62M | -20.16%58.11M | -41.34%62.24M | -33.74%104.4M | 213.85%150.87M | 12.15%203.92M | -49.89%72.78M | 446.39%106.09M | 286.86%157.57M | -462.59%-132.52M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -66.01%-40.38M | -297.19%-20.21M | -30.40%-8.15M | -54.40%-9.24M | 60.26%-2.78M | 38.25%-24.32M | 52.72%-5.09M | 66.59%-6.25M | -3,378.49%-5.98M | 28.21%-7.01M |
Capital expenditure reported | -27.18%-44.78M | -201.14%-20.52M | -19.48%-8.29M | 7.17%-9.24M | 41.56%-6.72M | 20.48%-35.21M | 36.68%-6.82M | 41.94%-6.94M | 0.74%-9.95M | 0.26%-11.5M |
Net business purchase and sale | -21.11%1.69M | -78.34%314K | ---- | ---- | ---- | 21.17%2.15M | --1.45M | ---- | ---- | ---- |
Net investment purchase and sale | --0 | --0 | --0 | --0 | --0 | 64.18%7.97M | ---599K | --0 | -58.68%4.07M | --4.49M |
Net other investing changes | 250.06%2.71M | --0 | ---1.23M | --0 | --3.94M | 144.53%773K | --876K | --0 | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -66.01%-40.38M | -297.19%-20.21M | -30.40%-8.15M | -54.40%-9.24M | 60.26%-2.78M | 38.25%-24.32M | 52.72%-5.09M | 66.59%-6.25M | -3,378.49%-5.98M | 28.21%-7.01M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 79.75%-110.22M | 87.49%-57.48M | -55.58%-46.82M | 164.93%17.21M | 18.29%-23.13M | -460.61%-544.44M | -2,617.97%-459.53M | -119.29%-30.09M | 25.28%-26.51M | 8.71%-28.31M |
Net issuance payments of debt | 93.74%-28.98M | 97.85%-9.31M | -360.33%-44.31M | 555.29%42.65M | -90.46%-18M | -1,139.36%-462.6M | -4,515.24%-434.16M | -2.61%-9.63M | 0.17%-9.37M | -3.27%-9.45M |
Net common stock issuance | 36.38%-4.63M | --0 | --0 | 45.09%-665K | 34.12%-3.96M | 67.44%-7.27M | 94.58%-42K | 99.52%-6K | -7,023.53%-1.21M | 70.37%-6.01M |
Proceeds from stock option exercised by employees | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net other financing activities | -2.76%-76.62M | -90.17%-48.17M | 87.75%-2.51M | -55.56%-24.78M | 90.91%-1.17M | -99.06%-74.56M | -276.65%-25.33M | -561.46%-20.46M | 38.92%-15.93M | -720.77%-12.85M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 79.75%-110.22M | 87.49%-57.48M | -55.58%-46.82M | 164.93%17.21M | 18.29%-23.13M | -460.61%-544.44M | -2,617.97%-459.53M | -119.29%-30.09M | 25.28%-26.51M | 8.71%-28.31M |
Net cash flow | ||||||||||
Beginning cash position | -38.65%570.58M | -14.53%816.38M | -10.17%802.55M | -9.61%690.52M | -38.65%570.58M | 4.23%930M | 20.77%955.19M | 9.30%893.37M | -7.02%763.93M | 4.23%930M |
Current changes in cash | 161.68%225.02M | 95.00%-19.59M | -89.57%7.27M | -10.15%112.38M | 174.45%124.95M | -904.78%-364.84M | -433.27%-391.84M | 636.62%69.76M | 2,361.18%125.08M | -160.92%-167.83M |
Effect of exchange rate changes | -302.20%-10.94M | -268.07%-12.14M | 182.53%6.55M | -107.91%-345K | -383.79%-5.01M | 171.65%5.41M | -66.39%7.23M | 40.83%-7.94M | 146.57%4.36M | 128.13%1.76M |
End cash Position | 37.52%784.65M | 37.52%784.65M | -14.53%816.38M | -10.17%802.55M | -9.61%690.52M | -38.65%570.58M | -38.65%570.58M | 20.77%955.19M | 9.30%893.37M | -7.02%763.93M |
Free cash flow | 96.10%330.84M | -43.02%37.59M | -45.60%53.94M | -35.53%95.17M | 200.09%144.15M | 22.64%168.71M | -50.95%65.97M | 1,228.91%99.15M | 380.78%147.61M | -310.50%-144.02M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |